BIOGEN INC. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31)
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) of $1.40 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax · last filed 2013-04-25
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $1.40M.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2012 was $486.00K, a 93.21% decline from fiscal 2011.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2011 was $7.16M, a 26.50% increase from fiscal 2010.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2013-01-31) for fiscal 2010 was $5.66M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2013-03-31 | $1.40M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $486.00K 10-K · filed 2013-02-05 | |
| 2011-12-31 | $7.16M 10-K · filed 2013-02-05 | |
| 2010-12-31 | $5.66M 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |